palivizumab (monoclonal antibody)
GPTKB entity
Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:approvedBy |
gptkb:FDA
1998 |
| gptkbp:ATCCode |
J06BB16
|
| gptkbp:CASNumber |
gptkb:188039-54-5
|
| gptkbp:developedBy |
gptkb:MedImmune
|
| gptkbp:halfLife |
20 days
|
| gptkbp:hasMolecularFormula |
C6418H9910N1694O1987S44
|
| https://www.w3.org/2000/01/rdf-schema#label |
palivizumab (monoclonal antibody)
|
| gptkbp:indication |
high-risk infants and children
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketedAs |
gptkb:Synagis
|
| gptkbp:mechanismOfAction |
neutralizes RSV by binding to F protein
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
fever
injection site reaction rash hypersensitivity reaction |
| gptkbp:target |
gptkb:RSV_F_protein
|
| gptkbp:UNII |
Q99T64V53U
|
| gptkbp:usedFor |
prevention of respiratory syncytial virus (RSV) infection
|
| gptkbp:WHOModelListOfEssentialMedicines |
no
|
| gptkbp:bfsParent |
gptkb:Respiratory_syncytial_virus
|
| gptkbp:bfsLayer |
7
|